2490556-50-6
2490556-50-6
Chemical Structure
Vobramitamab
Synonym(s): AEX-4089; MGC026 antibody
- CAS No.: 2490556-50-6
- Formula:N/A
- Molecular Weight:(144.691 kDa)
IUPAC Name: (E)-N,5-bis(4-chlorophenyl)-3-((propan-2-yl-d7)imino)-3,5-dihydrophenazin-2-amine
SMILES: [Vobramitamab]
Biological Activity: Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vobramitamab | 99.67% | Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Brignole C, et al. Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models[J]. Cancer Research, 2023, 83(7_Supplement): 2981-2981.
- [2]. Brignole C, et al. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. J Immunother Cancer. 2023 Sep;11(9):e007174. [Content Brief]
- [3]. Danielle C Kirkey MD, et al. CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate. Blood.Volume 142, Supplement 1, 2 November 2023, Page 5958
- [4]. Scribner JA, et al. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. Mol Cancer Ther. 2020 Nov;19(11):2235-2244. [Content Brief]
